B. Metzler seel. Sohn & Co. AG Has $10.20 Million Holdings in Pfizer Inc. (NYSE:PFE)

B. Metzler seel. Sohn & Co. AG lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 15.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 384,264 shares of the biopharmaceutical company’s stock after selling 69,227 shares during the period. B. Metzler seel. Sohn & Co. AG’s holdings in Pfizer were worth $10,195,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Retirement Wealth Solutions LLC bought a new stake in Pfizer during the fourth quarter worth $26,000. Rialto Wealth Management LLC purchased a new position in Pfizer during the 4th quarter worth $26,000. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer in the 4th quarter worth $28,000. Noble Wealth Management PBC purchased a new stake in shares of Pfizer in the fourth quarter valued at about $31,000. Finally, Curio Wealth LLC purchased a new position in Pfizer during the fourth quarter worth about $32,000. 68.36% of the stock is owned by institutional investors.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

PFE has been the topic of several recent analyst reports. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Truist Financial cut their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Citigroup lowered their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Bank of America restated a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. Finally, Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Price Performance

Shares of NYSE:PFE opened at $25.20 on Monday. The company has a 50 day moving average of $26.06 and a 200 day moving average of $26.90. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock has a market cap of $142.93 billion, a P/E ratio of 17.87, a P/E/G ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s quarterly revenue was up 24.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.10 earnings per share. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.